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Abstract
Background. The angiotensin-(1-7) is a new component of the renin-angiotensin system, the product of the degra-
dation of angiotensin II and its functional antagonist, but its role in hypertension with type 2 diabetes (T2D) is not 
clear. The aim of the study was to investigate the levels of angiotensin-(1-7) in patients with hypertension and T2D 
and determine its relations to hemodynamic and cardiac structural and functional parameters.
Material and methods. We examined 70 patients with hypertension and T2D. Investigation protocol included 
physical examination, standard transthoracic echocardiography and determination of the angiotensin-(1-7) blood 
levels by ELISA. Control group consisted of 16 healthy volunteers.
Results. The angiotensin-(1-7) levels in observed patients were significantly lower than in volunteers [105.51 
(89.13;121.17) ng/L vs. 132.75 (125.06; 142.87) ng/L, p < 0.001]. The levels of the angiotensin-(1-7) sig-
nificantly negatively correlated with duration of hypertension (r = –0.29, p < 0.05), systolic blood pressure (BP)  
(r = –0.38, p < 0.05), diastolic BP (r = –0.36, p < 0.01), average BP (r = –0.32, p < 0.01), left ventricular (LV) 
internal dimension at end-diastole (r = –0.37, p < 0.01), LV mass (r = –0.40, p < 0.001), LV mass index (r = –0.41,  
p < 0.001). In patients with LV hypertrophy, angiotensin-(1-7) levels were significantly lower than in patients  
without LV hypertrophy [101.9 (88.2; 117.7) ng/L vs. 129.3 (117.5; 136.8) ng/L, p < 0.01] and in patients with 
diastolic LV dysfunction — lower than in the patients with normal diastolic function [101.1 (87.9; 116.6) ng/L  
vs. 121.1 (105.5; 128.9) ng/L, p < 0.01].
Conclusions. The angiotensin-(1-7) can be considered as an important pathogenetic factor in the development of 
hypertension with T2D, a BP regulator and a cardioprotective agent that prevents the development of remodeling 
and diastolic dysfunction of the LV.
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Introduction
Hypertension and type 2 diabetes (T2D) are the 
most world-spread non-infectious diseases. Even 
individually, each of them is associated with an in-
creased risk of cardiovascular mortality. According to 
studies, more than 60% of patients with T2D have 
high blood pressure (BP). The prevalence of hyper-
tension among patients with T2D reaches 49%. It 
has been proved that T2D increases the cardiovas-
cular risk 2-fold in men, 3-fold in women and the 
presence of hypertension further increases the risk 
4-fold in patients with diabetes [1]. Nowadays, the 
scientists pay special attention to studying the influ-
ence of hormones, adipokines, endogenous peptides, 
and inflammation factors in the pathogenesis of both 
hypertension and diabetes [2–4].
The leading pathogenetic role in the develop-
ment of hypertension plays the renin-angiotensin 
system. In the classic sense, the renin-angiotensin 
system regulates the production of angiotensin II 
hormone from angiotensinogen. The renin and 
angiotensin-converting enzyme (ACE) type 1 is in-
volved in this process, and the pathophysiological 
response to angiotensin II is mainly realized via an-
giotensin receptors type 1 [5]. At the same time, in 
recent years, the knowledge about the mechanisms 
for the involvement of renin-angiotensin system in 
the development of cardiovascular diseases has been 
expanded by discovering and studying the effects of 
angiotensin II metabolites, which include angioten-
sin-(1-7) [6].
Angiotensin-(1-7) is a heptapeptide which is de-
rived from angiotensin II under the influence of 
ACE type 2. Angiotensin-(1-7) implements its physi-
ological role through specific Mas receptors that are 
widely represented in human tissues [7] and acts as 
a functional antagonist of angiotensin II, has antihy-
pertensive, antiremodeling, cardioprotective and an-
tiatherosclerotic properties, affects the development 
of heart failure, ischemic heart disease, arrhythmias 
[8, 9]. Presently, angiotensin-(1-7) and its synthetic 
analogs are considered as potential therapeutic agents 
in the treatment of a number of cardiovascular dis-
eases [10].
Despite the great progress in understanding the 
role of angiotensin-(1-7) in cardiovascular disease, 
studies involving patients with both hypertension 
and T2D are few. Thus, the aim of the study was to 
investigate the levels of angiotensin-(1-7) in patients 
with hypertension and T2D and determine its rela-
tions to hemodynamic and cardiac structural and 
functional parameters.
Material and methods
Study population
The study involved 70 patients with grade 2–3 hy-
pertension combined with T2D in the Department 
of Hypertension of Government Institution “L.T. 
Malaya Therapy National Institute of the NAMS of 
Ukraine”, Kharkiv. Definition and classification of 
hypertension, stratification of patients by total car-
diovascular risk was performed according to “2013 
ESH/ESC Guidelines” [11]. The T2D diagnosis was 
made according to “2013 ESC Guidelines on diabe-
tes, pre-diabetes, and cardiovascular diseases devel-
oped in collaboration with the EASD” [12].
Inclusion criteria for the study were age of pa-
tients more than 18 years, presence of combina-
tion of hypertension with T2D, informed consent 
signed by the patient. Exclusion criteria were as 
follows: malignant hypertension, symptomatic hy-
pertension, a history of myocardial infarction or 
stroke, secondary insulin-dependent diabetes, se-
vere heart failure and coronary heart disease, con-
genital heart disease, acute or chronic systemic in-
flammatory conditions, severe pulmonary, liver and 
kidney diseases, known or treated malignancies, 
and pregnancy.
Age of the patients ranged from 40 to 70 years, 
median age was 57 (52; 65) years. There were 34 man 
(48.6 %) and 36 women (51.4 %) among examined 
patients. Duration of hypertension in the patients 
was 15 (10; 20) years, diabetes duration was 4 (1; 6) 
years. Median level of systolic blood pressure (BP) 
was 170 (170; 180) mmHg and diastolic BP was 
110 (100; 110) mm Hg. Nineteen patients (27.1 %) 
had grade 2 hypertension and ,51 patients (72.9%) 
— grade 3 hypertension. Median level of glycated 
hemoglobin in patients with hypertension and T2D 
was 7.5% (7.1%; 7.8%)
The control group consisted of 16 healthy volun-
teers, who did not have history of any cardiovascular 
risk factors or illnesses.
Study protocol
All the participants were interviewed to obtain medi-
cal history. Physical examination was performed, in-
cluding measurements of height, body weight, and 
waist circumference. The BP measuring was per-
formed by auscultative method of Korotkov using 
a sphygmomanometer according to the standard 
method. The average BP was calculated as the sum 
of diastolic BP and one third of pulse BP. The pulse 
BP was defined as the difference between systolic and 
diastolic BP.
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Blood samples were drawn in the early morning 
from the antecubital vein of each subject after an 
overnight fasting period. Once drawn, the serum 
samples were centrifuged and immediately stored 
at –20°C prior to the analysis. Levels of angioten-
sin-(1-7) were measured by enzyme-linked immu-
nosorbent assay (ELISA), using ELISA kit of “YH 
Biosearch Laboratory”, China and automated ELISA 
assay system “ImmunoChem — 2100” (HTI, USA) 
according to the manufacturer’s instructions. 
All subjects underwent standard trans-thoracic 
echocardiographic examination on the day of serum 
collection. The examinations were carried out using 
a “ULTIMA PA” echocardiography machine (RAD-
MIR, Ukraine). All cardiac chamber measurements 
were made as suggested by the American Society of 
Echocardiography [13], including LV internal di-
mension at end-diastole (LVIDd), septal wall thick-
ness at end-diastole (SWTd), posterior wall thickness 
at end-diastole (PWTd), left atrium (LA) antero-
posterior linear dimension, diameter of the aortic 
root were measured using two-dimensional (2D) or 
M-mode images taken from parasternal long axis 
views of the heart. The LV ejection fraction was 
calculated using the LV volumes by the modified bi-
plane Simpson’s rule. LV mass (LVM) was calculated 
using the following formula: 
LVM = 0.80 × (1.04 [(LVIDd + PWTd + SWTd)3 
– (LVIDd)3]) + 0.6 g
Body surface area (BSA) was calculated by the 
Dubois formula: 
BSA = 0.007184 × height (cm)0.725 × weight (kg)0.425
LVM index was calculated by dividing the LVM 
by the BSA. LVH was estimated using thresholds 
of 95 g/m2 for women and 115 g/m2 for men [11]. 
Calculation of relative wall thickness (RWT) by the 
formula, (2 × PWTd)/LVIDd, permits categoriza-
tion of an increase in LV mass as either concentric 
(RWT ≥ 0.42) or eccentric (RWT < 0.42) LVH 
and allows identiﬁcation of concentric remodeling 
(normal LV mass with increased RWT). Normal LV 
geometry was determined as normal LV mass with 
normal RWT.
The diastolic function of LV was estimated from 
the data of the mitral inflow in pulsed-waved Dop-
pler mode from the apical 4-chamber view. Primary 
measurements of mitral inﬂow include the peak early 
ﬁlling (E-wave) and late diastolic ﬁlling (A-wave) 
velocities, the E/A ratio, deceleration time of early 
ﬁlling velocity the isovolumetric relaxation time of 
the myocardium. An indication of early diastolic 
function impairment was considered with a decrease 
in E/A of less than 0.8 (type I diastolic dysfunction). 
When the normal values of diastolic function were 
detected, an additional analysis of the Valsalva ma-
neuver was performed to determine the pseudonor-
mal pattern (type II diastolic dysfunction).
Statistical analysis
The data were analyzed with IBM SPSS Statistics 
version 19 (SPSS for Windows, Version 19.0., SPSS 
Inc., Chicago, IL, USA). The distribution of vari-
ables normality was tested with the Kolmogorov-
Smirnov test. The quantitative data were presented 
using median as a measure of position and quartile 
as a measure of dispersion. Continuous variables 
were defined as median (25 quartile; 75 quartile). 
The Mann-Whitney test was used to determine dif-
ferences between groups. The Kruskal-Wallis disper-
sion analysis was applied for evaluation of influ-
ence of angiotensin-(1-7) levels on hemodynamics 
and cardiac indicators. The relationships between 
levels of angiotensin-(1-7) and other clinical vari-
ables were examined using Spearman’s correlation. 
A value of p < 0.05 indicated a statistically signifi-
cant result.
Ethics statement
The protocol of the study was carried out accord-
ing to the principles of the Declaration of Helsinki 
and approved by local Ethics Committee (number: 
03.04.2012/10058) [14]. Written informed consent 
was obtained from all the participants before enrol-
ment.
Results
The blood levels of angiotensin-(1-7) in patients with 
hypertension and T2D were significantly lower than 
in healthy volunteers — 105.51 (89.13; 121.17) 
ng/L vs. 132.75 (125.06; 142.87) ng/L, p < 0.001 
(Fig. 1).
For Kruskal-Wallis dispersion analysis the levels 
of angiotensin-(1-7) were divided into three catego-
ries — more than 120.02 ng/L (norm), within the 
range of 100.79 — 120.01 ng/L (less than normal) 
and less than 100.79 ng/L (significantly less than 
normal). We evaluated the influence of angioten-
sin-(1-7) levels on hemodynamic and cardiac struc-
tural and functional parameters. The dispersion 
analysis results showed significant effect of blood 
angiotensin-(1-7) levels on systolic BP (p < 0.05), 
diastolic BP (p < 0.01), average BP (p < 0.01), 
arterial hypertension 2019, vol. 23, no. 3
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grade of hypertension (p < 0.05), LVIDd (p < 0.05), 
RWT (p < 0.05), LVM (p < 0.05), LVM index 
(p < 0.05), presence of diastolic dysfunction 
(p < 0.01) and type of diastolic dysfunction 
(p < 0.001) in patients with hypertension and T2D 
(Tab. I).
Correlation analysis revealed that in patients with 
hypertension and T2D the angiotensin-(1-7) levels 
significantly negatively correlate with duration 
of hypertension (r = –0.29, p < 0.05), hemody-
namic parameters such as systolic BP (r = –0.38, 
p < 0.05), diastolic BP (r = –0.36, p < 0.01), average BP 
(r = –0.32, p < 0.01) (Tab. II) and structural param-
eters of the LV such as LVIDd (r = –0.37, p < 0.01), 
LVM (r = –0.40, p < 0.001), LVM index (r = –0.41, 
p < 0.001) (Tab. III).
We analyzed the levels of angiotensin-(1-7), de-
pending on LV remodeling. In patients with LVH, 
angiotensin-(1-7) levels were significantly lower than 
in patients without LVH [101.9 (88.2; 117.7) ng/L 
vs. 129.3 (117.5; 136.8) ng/L, p < 0.01]. Depend-
ing on the type of LV remodeling in patients with 
concentric LVH and eccentric LVH, the angioten-
sin-(1-7) levels were significantly lower compared 
with those with concentric remodeling of LV [107.5 
(88.2; 119.6) ng/L and 101.4 (84.2; 111.8) ng/L vs. 
129.3 (117.5; 136.8) ng/L, p < 0.01 and p < 0.01 
respectively], but probably did not differ from each 
other (p > 0.05) (Fig. 2). 
Depending on the diastolic function of LV in 
patients with hypertension and T2D, the levels of 
angiotensin-(1-7) were significantly different in dif-
ferent subgroups. In the presence of diastolic LV 
dysfunction, the concentration of angiotensin-(1-7) 
was significantly lower than in the subgroup with 
normal diastolic function — 101.1 (87.9; 116.6) 
ng/L vs. 121.1 (105.5; 128.9) ng/L (p < 0.01). At the 
same time, the levels of angiotensin-(1-7) were found 
to be the lowest in the subgroup with type II diastolic 
dysfunction and significantly different from its levels 
in the subgroup with normal diastolic function [97.2 
(81.2; 105.4) ng/L vs. 121.1 (105.5; 128.9) ng/L, 
p < 0.01] and in the subgroup with type I diastolic 
Figure 1. The angiotensin-(1-7) blood levels in patients with hyper-
tension with type 2 diabetes (T2D) and in control group
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Table I. Kruskal-Wallis dispersion analysis results
Parameters c2 p
Systolic BP 8.881 < 0.05
Diastolic BP 9.663 < 0.01
Average BP 11.723 < 0.01
Grade of hypertension 8.974 < 0.05
LVIDd 7.83 < 0.05
SWTd 4.281 > 0.05
PWTd 5.248 > 0.05
RWT 8.45 < 0.05
LVM 8.686 < 0.05
LVM index 8.341 < 0.05
LA anteroposterior linear dimension 5.604 > 0.05
Diastolic dysfunction 11.829 < 0.01
Type of diastolic dysfunction 17.031 < 0.001
BP — blood pressure; LVIDd — left ventricular internal dimension at end-diastole; SWTd — septal 
wall thickness at end-diastole; PWTd — posterior wall thickness at end-diastole; RWT — relative wall 
thickness; LVM — left ventricle mass; LV — left ventricle; LA — left atrium
Table II. The correlations of angiotensin-(1-7) with hemodynamic 
parameters
Hemodynamic parameters r p
Duration of hypertension –0.29 < 0.05
Systolic BP –0.38 < 0.01
Diastolic BP –0.36 < 0.01
Average BP –0.32 < 0.01
BP — blood pressure
Table III. The correlations of angiotensin-(1-7) with cardiac struc-
tural parameters
Heart indicators r p
LVIDd –0.37 < 0.01
SWTd –0.21 > 0.05
PWTd –0.21 > 0.05
RWT 0.10 > 0.05
LVM –0.40 < 0.001
LVM index –0.41 < 0.001
LV ejection fraction 0.15 > 0.05
LA anteroposterior linear dimension –0.19 > 0.05
LVIDd — left ventricular internal dimension at end-diastole; SWTd — septal wall thickness at end-dia-
stole; PWTd — posterior wall thickness at end-diastole; RWT — relative wall thickness; LVM — left 
ventricle mass; LV — left ventricle; LA — left atrium
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dysfunction [97.2 (81.2; 105.4) ng/L vs. 106.9 (88.2; 
122.2) ng/L, p < 0.05]. In patients with type I dia-
stolic dysfunction, the levels of angiotensin-(1-7) did 
not differ significantly from those in patients with 
normal diastolic function (p = 0.07) (Fig. 3).
Discussion
The obtained results are of considerable scientific 
and practical interest. According to the literature 
data, the number of direct references to chang-
es in levels of angiotensin-(1-7) in patients with 
hypertension is very limited. One study showed 
a fourfold decrease in levels of angiotensin-(1-7) 
in patients with hypertension with a certain ACE 
type 1 genotype [15]. According to other authors, 
the administration of angiotensin-(1-7) caused se-
vere vasodilatation in patients with hypertension 
[16], which may indirectly indicate a deficiency of 
this peptide. Several experimental models show the 
important role of angiotensin-(1-7) in preventing 
systemic hypertension [17, 18] and vasodilation 
regulation [19, 20]. In rats with hypertension, in-
duction of diabetes caused a decrease in levels of 
angiotensin-(1-7), and increased levels prevented 
cardiovascular dysfunction, which develops in hy-
pertension with diabetes [21]. In transgenic models 
of animals with overexpression of angiotensin-(1-7), 
induction of hypertension caused a decrease in levels 
of angiotensin-(1-7) in the peripheral blood flow 
with a local increase of this peptide in the heart 
[22]. In our study, there are clear associations of 
angiotensin-(1-7) deficiency with the development 
of hypertension in combination with T2D. Nega-
tive correlations of angiotensin-(1-7) levels with the 
main hemodynamic parameters indicate the regula-
tory role of angiotensin-(1-7) in BP.
We obtained interesting data about the relation-
ship between the levels of angiotensin-(1-7) and 
pathological remodeling of LV in patients with hy-
pertension and T2D. According to our results, the 
levels of angiotensin-(1-7) are decreased in patients 
with LVH and correlate negatively with LVIDd, 
LVM and LVM index, indicating cardiac antiremod-
eling properties of angiotensin-(1-7). This conclu-
sion is confirmed by data from other studies. Pa-
tients with aortic stenosis and LVH have deficiency 
of angiotensin-(1-7) compared with healthy subjects 
[23]. In the experiment, it was shown that angioten-
sin-(1-7) decreases angiotensin II induced cardiac 
hypertrophy in rats [24, 25], including animals with 
insulin resistance [26], and prevents hyperglycemia-
induced cardiomyocyte lesion [27].
The association of angiotensin-(1-7) with LV func-
tion has been shown in patients with T2D, in whom 
angiotensin-(1-7) levels were associated with both sys-
tolic and diastolic dysfunction [27]. Our study con-
firms this thesis as it was found that angiotensin-(1-7) 
levels depend on both the presence of diastolic dys-
function and its type. According to experimental data, 
hyperexpression of angiotensin-(1-7) prevents the 
occurrence of diastolic dysfunction and remodeling 
of LV in rats [21]. Cardioprotective mechanisms of 
angiotensin-(1-7) have not been fully understood, but 
scientists assume that they are associated with a de-
crease in oxidative stress and inflammation through 
the effect on the Mas receptors [28, 29].
Our study has several limitations. The present 
study has the relatively small number of patients. 
Angiotensin-(1-7) levels were measured only once 
during hospitalization. Its levels and relations with 
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Figure 3. The angiotensin-(1-7) levels in patients with hypertension 
and type 2 diabetes (T2D) depending on diastolic function of left 
ventricle (LV)
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Figure 2. The angiotensin-(1-7) blood levels in patients with hy-
pertension and type 2 diabetes (T2D) depending on the type of left 
ventricle (LV) remodeling; LVH — left ventricle hypertrophy
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cardiac parameters in response to different variants 
of antihypertensive treatment were not evaluated. 
We could not assess cardiac remodeling and cardio-
vascular events depending on basal angiotensin-(1-7) 
concentrations in long-term period.
Despite the limitations of this study, it appears 
that angiotensin-(1-7) can be considered as an im-
portant pathogenetic factor in the development of 
hypertension with T2D, a BP regulator and a car-
dioprotective agent that prevents the development 
of remodeling and diastolic dysfunction of the LV.
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